Plain-English translation of NCT07304817 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a newer medication called vicadrostat against an older, well-known medication called spironolactone to see which one works better for protecting your kidneys and heart. Both medications work in similar ways but through slightly different mechanisms. The study wants to understand how each medication affects your kidney function, heart health, and proteins in your blood and urine.
Doctors know that both types of these medications can help protect kidneys and hearts in certain patients, but they've never directly compared them side-by-side in people with both kidney disease and heart problems. This medication is newer and may work differently, so researchers want to see if it offers any advantages.
You likely qualify if…
You likely don't qualify if…
You would take a daily pill of either the new medication or the comparison medication for 26 weeks, along with empagliflozin. You would visit the clinic at the start, after 4 weeks, and after 26 weeks to have your kidney function and heart health checked through blood tests and other measurements. About half of participants will also have additional imaging tests to measure how blood flows through the kidneys at baseline, week 4, and week 26.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Netherlands